HOME >> BIOLOGY >> NEWS
The long road to a promising malaria vaccine started at NYU School of Medicine

NEW YORK, October 15, 2004 -- The malaria vaccine reported today to reduce life-threatening cases of the parasitic disease among children in Mozambique is based on the pioneering research of Drs. Ruth and Victor Nussenzweig and their colleagues at NYU School of Medicine.

Ruth Nussenzweig, Doc en Med, Ph.D., the C.V. Starr Professor of Medical and Molecular Parasitology, and her husband, Victor Nussenzweig, M.D., Ph.D., the Hermann M. Biggs Professor of Preventive Medicine, have devoted decades of research to preventing one of the world's biggest killers. Malaria afflicts hundreds of millions of people, causing up to 3 million deaths every year, mostly in sub-Saharan Africa. Many of its victims are young children.

In a study reported today of more than 2,000 children in Mozambique, the vaccine reduced life-threatening attacks of malaria by 58 percent, and reduced milder forms of the disease by 30 percent. The study is published in the October 16, 2004, issue of The Lancet, a medical journal.

"This is really fantastic news," says Dr. Victor Nussenzweig. "It is the first time that a vaccine has been shown to protect against severe malaria, which is a major cause of death in children in Africa. It is not yet an ideal vaccine because it is expensive, requires three doses, and it isn't known yet how durable the vaccine's protection will be, but it is a very big step forward."

The vaccine, designated RTS.S/AS02A, contains a large portion of a protein called circumsporozoite (CS) protein, which coats malaria parasites that invade the liver. This protein, which the Nussenzweigs first isolated from parasites in 1980, is the basis for some 15 malaria vaccines that now are in clinical trials or in pre-clinical testing.

The vaccine, developed by GlaxoSmithKline in collaboration with the Walter Reed Army Institute of Research, contains a large portion of the CS protein fused with a part of another
'"/>

Contact: Pamela McDonnell
Pamela.McDonnell@med.nyu.edu
212-404-3555
New York University Medical Center and School of Medicine
15-Oct-2004


Page: 1 2 3

Related biology news :

1. A new plant-bacterial symbiotic mechanism promising
2. A new plant-bacterial symbiotic mechanism promising for crop applications
3. American Association for Cancer Research provides support for promising cancer scientists
4. Sea creatures toxin could lead to promising cancer treatment
5. Epigenetic drugs, promising for breast cancer treatment
6. New study suggests promising drug combinations for sleeping sickness
7. Analysis of breast-cancer gene role offers promising target
8. Researchers report initial success in promising approach to prevent tooth decay
9. DNA highly promising predictor for successful treatment of alcoholics
10. Stem cells: Chemistry paves way toward promising therapies
11. Is liver damage down the TRAIL for a promising cancer therapy?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/19/2016)... 2016 Securus Technologies, a leading provider of ... investigation, corrections and monitoring, announced today that it has ... have an independent technology judge determine who has the ... tech/sophisticated telephone calling platform, and the best customer service. ... most of what we do – which clearly is ...
(Date:11/15/2016)... -- Research and Markets has announced the addition of ... to their offering. ... The global bioinformatics ... USD 6.21 Billion in 2016, growing at a CAGR of 21.1% ... market is driven by the growing demand for nucleic acid and ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... , ... December 06, 2016 ... ... Great Point Partners ("GPP") portfolio company, today announced it has acquired the ... a subsidiary of Chiltern International and focuses on clinical trial drug packaging, ...
(Date:12/6/2016)... Ind. , Dec. 6, 2016 Zimmer ... "Company") today announced the pricing terms of its ... to $1.25 billion aggregate purchase price (excluding accrued and ... settlement date and excluding fees and expenses related ... the debt securities identified in the table below ...
(Date:12/6/2016)... Toronto, ON (PRWEB) , ... ... ... (“ProMIS” or the “Company”), a company focused on discovery and development of ... therapeutic candidates it is developing for Alzheimer’s disease (AD) inhibited the direct ...
(Date:12/5/2016)... ... December 05, 2016 , ... This composition patent, U.S. Patent ... The composition claims are not limited to any particular process to make ... polymers, carbon fibers, graphene, and other materials. A continuation application, U.S. Patent ...
Breaking Biology Technology:
Cached News: